'As more patients are prescribed these drugs, intolerance due to gastrointestinal and other side effects will become more visible, leading to higher discontinuation rates.'
The company has received final approval for its supplemental New Drug Application (sNDA) for Antara (Fenofibrate) capsules in 30 mg and 90 mg strengths from the United States Food and Drug Administration (USFDA), Lupin Ltd said in a statement.
Lupin Pharmaceuticals has bought the US marketing rights of cholestrol-lowering drug Antara and related assets from bankrupt American entity Oscient Pharmaceuticals for $38.61 million
